Impact of Chemotherapy on Renal Parameters and Treatment Outcomes in Nasopharyngeal Carcinoma Patients: A Retrospective Study at Santa Elisabeth Hospital Batam
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Nasopharyngeal carcinoma (NPC) poses a unique challenge, with distinct epidemiology and aggressive behavior. Chemotherapy plays a central role in NPC treatment, yet its impact on renal parameters remains a nuanced domain. This retrospective cohort study at Santa Elisabeth Hospital, Batam, delves into the dynamic interplay between chemotherapy and renal function in NPC patients. Electronic medical records of NPC patients undergoing chemotherapy were analyzed, focusing on urea levels, creatinine levels, and glomerular filtration rate (GFR). Statistical analyses, including paired t-tests and subgroup analyses based on chemotherapy regimens, were employed. Initial chemotherapy cycles induced a transient elevation in urea and creatinine levels, indicative of potential renal stress. Subsequent cycles revealed a trend toward stabilization or mild decline. GFR demonstrated a progressive but acceptable reduction, varying across chemotherapy regimens. Platinum-based regimens correlated with more pronounced alterations in urea and creatinine levels, while taxane-containing regimens exhibited a distinct impact on GFR. Patterns observed offer insights into personalized treatment approaches, guiding clinicians in optimizing therapeutic efficacy while safeguarding renal health. This research contributes not only to immediate patient care but also to the broader landscape of oncological knowledge, influencing future research agendas and evidence-based guidelines.
##plugins.themes.bootstrap3.article.details##
Basu, I., & Perry, M. (2021). Initial Assessment of the “Head and Neck” Patient. Diseases and Injuries to the Head, Face and Neck: A Guide to Diagnosis and Management, 57–134.
Brennan, B. (2006). Nasopharyngeal carcinoma. Orphanet Journal of Rare Diseases, 1(1), 1–5.
Coleman, M. D. (2020). Human drug metabolism. John Wiley & Sons.
Fidalgo, S. C. P. de P. (2019). Assessment of the Effect of Renal Impairment on the Pharmacokinetics.
Krstic, D., Tomic, N., Radosavljevic, B., Avramovic, N., Dragutinovic, V., Skodric, S. R., & Colovic, M. (2016). Biochemical markers of renal function. Current Medicinal Chemistry, 23(19), 2018–2040.
Lee, A. W. M., Lung, M. L., & Ng, W. T. (2019). Nasopharyngeal carcinoma: from etiology to clinical practice. Academic Press.
Li, L., Mok, H., Jhaveri, P., Bonnen, M. D., Sikora, A. G., Eissa, N. T., Komaki, R. U., & Ghebre, Y. T. (2018). Anticancer therapy and lung injury: molecular mechanisms. Expert Review of Anticancer Therapy, 18(10), 1041–1057.
Paiar, F., Di Cataldo, V., Zei, G., Pasquetti, E. M., Cecchini, S., Meattini, I., Mangoni, M., Agresti, B., Iermano, C., & Bonomo, P. (2012). Role of chemotherapy in nasopharyngeal carcinoma. Oncology Reviews, 6(1).
Petersson, F. (2015). Nasopharyngeal carcinoma: a review. Seminars in Diagnostic Pathology, 32(1), 54–73.
Porta, C., Cosmai, L., Gallieni, M., Pedrazzoli, P., & Malberti, F. (2015). Renal effects of targeted anticancer therapies. Nature Reviews Nephrology, 11(6), 354–370.
Raab-Traub, N. (2002). Epstein–Barr virus in the pathogenesis of NPC. Seminars in Cancer Biology, 12(6), 431–441.
Rachman, A., Shatri, H., & Salamat, R. (2021). Correlation between higher cumulative dose of cisplatin for concurrent chemoradiation and acute kidney disease incidence among nasopharyngeal carcinoma patients: a comparative study. International Journal of General Medicine, 10527–10539.
Roberto, M., Panebianco, M., Aschelter, A. M., Buccilli, D., Cantisani, C., Caponnetto, S., Cortesi, E., d’Amuri, S., Fofi, C., & Ierinò, D. (2023). The value of the multidisciplinary team in metastatic renal cell carcinoma: Paving the way for precision medicine in toxicities management. Frontiers in Oncology, 12, 1026978.
Smatti, M. K., Al-Sadeq, D. W., Ali, N. H., Pintus, G., Abou-Saleh, H., & Nasrallah, G. K. (2018). Epstein–Barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: an update. Frontiers in Oncology, 8, 211.
Sun, D. (2006). Epigenetics in nasopharyngeal carcinoma. Karolinska Institutet (Sweden).
Wee, J., Nei, W. L., Yeoh, K. W., Yeo, R. M., Loong, S. L., & Qian, C.-N. (2012). Why are East Asians more susceptible to several infection-associated cancers (carcinomas of the nasopharynx, stomach, liver, adenocarcinoma of the lung, nasal NK/T-cell lymphomas)? Medical Hypotheses, 79(6), 833–842.
Wong, K. C. W., Hui, E. P., Lo, K.-W., Lam, W. K. J., Johnson, D., Li, L., Tao, Q., Chan, K. C. A., To, K.-F., & King, A. D. (2021). Nasopharyngeal carcinoma: an evolving paradigm. Nature Reviews Clinical Oncology, 18(11), 679–695.
Yonkers, N. Y. (1995). ona.-nāci≈ n Riggō-Ivanog, Neonge N. JO. CA... Low-on. Morbidity and Mortality Weekly Report: MMWR, 44(1–27), 111.
Zhang, L., Chen, Q.-Y., Liu, H., Tang, L.-Q., & Mai, H.-Q. (2013). Emerging treatment options for nasopharyngeal carcinoma. Drug Design, Development and Therapy, 37–52.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.